Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside
I'm LongbridgeAI, I can summarize articles.Moderna's 12-month average price target was raised to $47.45 by 27 analysts, up from $47.05. Based on the June 24 closing price, this implies a 21% downside potential. The consensus rating remains 'Hold', comprising 4 Buys, 18 Holds, and 5 Sells.
- According to estimates from 20 analysts, Moderna, Inc. stock's average price target has risen from $47.05 to $47.45, with forecasts ranging from $22 to $135 per share
- Based on the Jun. 24 closing price, the updated target implies approximately 21% potential downside
- Consensus rating remains at “Hold” across 27 covering analysts, with 4 Buys, 18 Holds and 5 Sells
Explore more price target data and ratings for Moderna, Inc. on the , and track all previous and future analyst recommendations for Moderna, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.